Tfg Advisers LLC Fate Therapeutics Inc Transaction History

Tfg Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	SELL	$17.78 - $42.39 $142,257 - $339,162	-8,001 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$29.67 - $60.28 $7,803 - $15,853	-263 Reduced 3.18%	8,001 $310,000
Q4 2021 Feb 01, 2022	SELL	$47.84 - $64.34 $19,470 - $26,186	-407 Reduced 4.69%	8,264 $484,000
Q3 2021 Oct 21, 2021	BUY	$59.27 - $95.73 $16,239 - $26,230	274 Added 3.26%	8,671 $514,000
Q2 2021 Jul 19, 2021	SELL	$67.25 - $92.52 $9,885 - $13,600	-147 Reduced 1.72%	8,397 $729,000
Q1 2021 Apr 23, 2021	SELL	$72.16 - $117.4 $5,339 - $8,687	-74 Reduced 0.86%	8,544 $704,000
Q4 2020 Feb 02, 2021	BUY	$38.09 - $100.95 $42,317 - $112,155	1,111 Added 14.8%	8,618 $783,000
Q3 2020 Nov 02, 2020	BUY	$30.41 - $40.5 $228,287 - $304,033	7,507 New	7,507 $300,000
Q1 2020 Apr 24, 2020	SELL	$17.28 - $31.88 $37,739 - $69,625	-2,184 Closed	0 $0
Q4 2019 Mar 16, 2020	BUY	$13.39 - $20.73 $29,243 - $45,274	2,184 New	2,184 $42,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Tfg Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Tfg Advisers LLC with notifications on news.